Acoramidis
Last Updated: 11/08/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 121 publications
Carpal Tunnel Syndrome and Lumbar Spinal Stenosis: When to Suspect Amyloidosis and How to Proceed with the Diagnostic Work-up
Journal: Brain and nerve = Shinkei kenkyu no shinpo
Published: October 13, 2026
Molecular imaging of TTR amyloidosis: New data.
Journal: Hellenic journal of nuclear medicine
Published: September 14, 2026
A trial emulation study indirectly comparing tafamidis and acoramidis in transthyretin amyloid cardiomyopathy: the ReplicATTR study.
Journal: Journal of comparative effectiveness research
Published: September 14, 2026
Natriuretic Peptide and Transthyretin and Their Relationship With Clinical Outcomes: Results From ATTRIBUTE-CM, a Randomized Controlled Trial.
Journal: Journal of the American Heart Association
Published: August 31, 2026
Pathophysiology and Comprehensive Pharmacological Management of ATTR Cardiac Amyloidosis: Knowledge Gaps, Ongoing Clinical Trials, and Future Research Directions.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: August 28, 2026
Implications of Serum Transthyretin to NT-proBNP Ratio in Transthyretin Amyloid Cardiomyopathy: Insights From ATTRibute-CM.
Journal: JACC. Heart failure
Published: August 26, 2026
Effect of acoramidis on risk of death and heart problem-related hospitalizations in people with transthyretin amyloid cardiomyopathy: a plain language summary.
Journal: Future cardiology
Published: August 05, 2026
Combination Therapy in ATTR Cardiomyopathy: Hypothesis-Generating, Not Yet Practice-Changing.
Journal: Journal of the American College of Cardiology
Published: August 05, 2026
Plain language summary of how acoramidis affects the total number of heart problems over time in people with ATTR-CM: findings from the ATTRibute-CM study.
Journal: Future cardiology
Published: August 03, 2026
Effect of Acoramidis on Heart Failure-Related Health Status: A Secondary Analysis of the ATTRibute-CM Randomized Clinical Trial.
Journal: JAMA cardiology
Published: July 29, 2026
Patient-Reported Benefits of Acoramidis Across Genotypes in Transthyretin Amyloid Cardiomyopathy: KCCQ and EQ-5D-5L Outcomes From ATTRibute-CM.
Journal: Journal of cardiac failure
Published: July 28, 2026
Closing the diagnostic gap in transthyretin cardiac amyloidosis: red flags, modern imaging, and emerging therapies.
Journal: Frontiers in cardiovascular medicine
Published: July 13, 2026
Last Updated: 11/08/2026